Showing results for "Sarepta"
markets
Hedge Funds Add Amazon, Intel, Cut Nike, Pfizer: 13F WrapHedge funds bought into some of the biggest technology names in the fourth quarter to chase a scorching rally in the sector fueled by the growth in artificial intelligence, according to the latest quarterly reports investment managers filed with the US Securities and Exchange Commission.February 15, 2024
politics
FDA’s Woodcock to Retire After Career Marked by ControversyUS Food and Drug Administration Deputy Commissioner Janet Woodcock will retire next year after nearly four decades at the regulator that were marked by controversy over support for unproven medications for rare, serious conditions.November 16, 2023
industries
FDA Hearing Targets Unproven $900,000 Drug for Deadly CancerThe cancer drug Folotyn, one of the most expensive in the US, received a short-cut approval from US regulators to treat a rare form of lymphoma 14 years ago, but officials still don’t have conclusive evidence it works.November 16, 2023
industries
Sarepta, Roche Slide After Gene Therapy Trial Misses GoalSarepta Therapeutics Inc. and Roche Holding AG slumped after the partners’ trial of a gene therapy for Duchenne muscular dystrophy failed to meet the main goal of a study, raising doubts that the treatment will be expanded to older children.October 31, 2023